$5.55▴ 3.54%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+184.5%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Moderatedebt to assets
Watch
Elevated leverage worth keeping an eye on.
More coming: dilution / share-count creep.
✦ The read
ARS Pharmaceuticals, Inc.'s earnings-quality signal is not available yet. Revenue is growing strongly year over year. Elevated leverage worth keeping an eye on.
Key numbers
Recent news
Sentiment · last 30 days2 articles
0 bullish0 neutral2 bearish
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed ARS Pharmaceutic (SPRY)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of ARS Pharmaceuticals, Inc. Securities and Sets a Lead Plaintiff Deadline of October 5, 2026
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.